Table 2.

Main characteristics of patients with DLBCL according to the occurrence of CNS event

	All patients (n = 2203)	Patients without CNS event (n = 2163)	Patients with CNS event (n = 40)	P value∗
Male, n (%)	1292 (59)	1266 (59)	26 (65)	.410
Female, n (%)	911 (41)	897 (41)	14 (35)
Age, median (range), y	47 (18-60)	47 (18-60)	51 (19-60)	.370
LDH > upper normal value, n (%)	1102 (50)	1070 (49)	32 (80)	<.001
ECOG >1, n (%)	193 (9)	183 (8)	10 (25)	.002
Stage III/IV, n (%)	1031 (47)	1003 (46)	28 (70)	.003
aaIPI, n (%)
0	652 (30)	651 (30)	1 (2)	<.001
1	924 (42)	906 (42)	18 (45)
2	479 (22)	468 (22)	11 (28)
3	148 (7)	138 (6)	10 (25)
Extralymphatic involvement, n (%)	1210 (55)	1183 (55)	27 (68)	.107
Extralymphatic involvement >1, n (%)	509 (23)	496 (23)	13 (32)	.155
Bulky disease† (>10 cm), n (%)	462 (21)	448 (21)	14 (35)	.029
B symptoms, n (%)†	654 (30)	635 (29)	19 (49)	.009
BM involvement, n (%)	142 (6)	135 (6)	7 (18)	.012
Kidney involvement at staging, n (%)	56 (3)	53 (2)	3 (8)	.079
Adrenal gland involvement at staging, n (%)	33 (1)	31 (1)	2 (5)	.119
Kidney and/or adrenal gland involvement at staging, n (%)	81 (4)	77 (4)	4 (10)	.057
CNS-IPI, n (%)
0	640 (29)	639 (30)	1 (2)	<.001
1	759 (34)	744 (34)	15 (38)
2	414 (19)	403 (19)	11 (28)
3	251 (11)	245 (11)	6 (15)
4	119 (5)	116 (5)	3 (8)
5	20 (1)	16 (1)	4 (10)
CNS-IPI groups, n (%)				.002
0-1, low risk	1399 (64)	1383 (64)	16 (40)
2-3, intermediate risk	665 (30)	648 (30)	17 (42)
4-5, high risk	139 (6)	132 (6)	7 (18)
MTX prophylaxis (at least 1 course), n (%)				—
MTX IT†	780 (38)	766 (38)	14 (40)
HD MTX IV	344 (16)	342 (16)	2 (5)
CNS event, n (%)		—		—
At first progression/relapse (within the first 3 y)	33 (1.5) (27)		33 (82) (27)
After first progression/relapse (within the first 3 y)	7 (0.3) (4)		7 (18) (4)

^∗P value for the comparison of patients with CNS failure vs patients without CNS event.

^†Some missing values: bulky disease (9/9/0), B symptoms (7/6/1), and MTX IT (143/138/5).